JPWO2022125891A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022125891A5
JPWO2022125891A5 JP2023535317A JP2023535317A JPWO2022125891A5 JP WO2022125891 A5 JPWO2022125891 A5 JP WO2022125891A5 JP 2023535317 A JP2023535317 A JP 2023535317A JP 2023535317 A JP2023535317 A JP 2023535317A JP WO2022125891 A5 JPWO2022125891 A5 JP WO2022125891A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
alkyldiyl
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501453A5 (https=
JP2024501453A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062797 external-priority patent/WO2022125891A2/en
Publication of JP2024501453A publication Critical patent/JP2024501453A/ja
Publication of JP2024501453A5 publication Critical patent/JP2024501453A5/ja
Publication of JPWO2022125891A5 publication Critical patent/JPWO2022125891A5/ja
Withdrawn legal-status Critical Current

Links

JP2023535317A 2020-12-11 2021-12-10 抗ceaイムノコンジュゲート、及びそれらの使用 Withdrawn JP2024501453A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124353P 2020-12-11 2020-12-11
US63/124,353 2020-12-11
PCT/US2021/062797 WO2022125891A2 (en) 2020-12-11 2021-12-10 Anti-cea immunoconjugates, and uses thereof

Publications (3)

Publication Number Publication Date
JP2024501453A JP2024501453A (ja) 2024-01-12
JP2024501453A5 JP2024501453A5 (https=) 2024-12-10
JPWO2022125891A5 true JPWO2022125891A5 (https=) 2024-12-10

Family

ID=79425667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535317A Withdrawn JP2024501453A (ja) 2020-12-11 2021-12-10 抗ceaイムノコンジュゲート、及びそれらの使用

Country Status (6)

Country Link
US (1) US20240238430A1 (https=)
EP (1) EP4259210A2 (https=)
JP (1) JP2024501453A (https=)
CN (1) CN116635084A (https=)
CA (1) CA3200051A1 (https=)
WO (1) WO2022125891A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023154318A1 (en) * 2022-02-09 2023-08-17 Bolt Biotherapeutics, Inc. Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
WO2005086875A2 (en) 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
LT1976880T (lt) 2005-12-21 2016-10-10 Amgen Research (Munich) Gmbh Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック, インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
RS56793B1 (sr) 2011-03-02 2018-04-30 Roche Glycart Ag Cea antitela
HUE033369T2 (en) 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
US9676863B2 (en) 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
AU2019337654A1 (en) * 2018-09-12 2021-04-08 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
WO2020252254A1 (en) * 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Macromolecule-supported aminobenzazepine compounds
AU2020291014B2 (en) * 2019-06-13 2025-06-05 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
CN115996756A (zh) * 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途

Similar Documents

Publication Publication Date Title
JP2024059609A5 (https=)
JPWO2020252294A5 (https=)
KR20250004686A (ko) 항체-약물 접합체, 및 이의 제조 방법 및 용도
KR20190085539A (ko) 항체-약물 접합을 위한 이-치환된 말레익 아미드 링커 및 이의 제조 방법 및 용도
JPWO2019213005A5 (https=)
JPWO2021213434A5 (https=)
JP2025533758A (ja) 抗体-薬物複合体並びにその調製方法及び使用
JPWO2021226440A5 (https=)
JPWO2021055295A5 (https=)
JPWO2021067242A5 (https=)
CA3258612A1 (en) Antibody drug conjugates
JPWO2022022508A5 (https=)
JPWO2021081407A5 (https=)
JPWO2022272039A5 (https=)
JPWO2022246576A5 (https=)
JPWO2022125884A5 (ja) 抗cea免疫複合体、及びその使用
JPWO2022125891A5 (https=)
JPWO2022125904A5 (https=)
JPWO2022125915A5 (https=)
JPWO2022125908A5 (https=)
JPWO2022204536A5 (https=)
JPWO2021225892A5 (https=)
JPWO2021046112A5 (https=)
JPWO2022036101A5 (https=)
JPWO2023154307A5 (https=)